Advances in treating metastatic castration-resistant prostate cancer
A&S Science Previous    

Advances in treating metastatic castration-resistant prostate cancer

Joanne Francis Advanced research practitioner, Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge, Wirral

For many years, there were no life-extending therapies for men with castration-resistant prostate disease. Joanne Francis discusses two options that have become available in the past year

New and emerging treatments with the potential to extend survival are reshaping and extending the management pathway for men with metastatic castration-resistant prostate cancer. To maximise the likely benefit for each individual patient, careful consideration must be given to the timing of treatment, the sequence in which the various agents are used and the proactive management of treatment-related side effects. This article considers the recent advances in this setting, and the associated nursing issues, with reference to the experience of a UK oncology centre.

Cancer Nursing Practice. 11, 6,32-37. doi: 10.7748/cnp2012.07.11.6.32.c9203

Correspondence

Joanne.Francis@ccotrust.nhs.uk

Conflict of interest

The author received editorial support from Succinct Healthcare Communications in the production of this manuscript, which was funded by Sanofi Oncology. Sanofi had no influence on the content of the article, and all the opinions expressed are the author’s own

Peer review

This article has been subject to double blind peer review

You need a subscription to read the full article